logo-loader
viewAIM ImmunoTech Inc.

Medsea Estates Group - Director/PDMR Shareholding

RNS Number:2296O Medsea Estates Group PLC 18 February 2008 Medsea Estates Group plc ('Medsea' or 'the Company') Director/PDMR shareholding Medsea Estates Group plc (AIM: MEA), the Mediterranean-based property group, was notified today that Neil Craven, non-executive director, purchased 50,000 shares at 2.5p per share on Friday 15th February, increasing his holding in the Company to 1,050,000 shares representing 1.35% of the issued shares. This information is provided by RNS The company news service from the London Stock Exchange END RDSBSGDDIUBGGII

Quick facts: AIM ImmunoTech Inc.

Price: 0.4851

Market: NYSE
Market Cap: $2.35 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

on 08/19/2019

RNS